3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
14
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
6
Urinary Bladder Neoplasms
4
Endometrial Neoplasms
3
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Uterine Cervical Neoplasms
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Metastatic Solid Tumors
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
180
Cisplatin
44
Paclitaxel
41
Carboplatin
41
lenvatinib
31
Docetaxel
22
Pemetrexed
20
Fluorouracil
19
Capecitabine
16
Gemcitabine
15
Saline Solution
13
Oxaliplatin
13
Albumin-Bound Paclitaxel
10
epacadostat
9
130-nm albumin-bound paclitaxel
9
Leucovorin
8
Cetuximab
8
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
belzutifan
5
Dexamethasone
5
enzalutamide
4
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
sacituzumab govitecan
×
Clear all
NCT05609968
2025-12-24
MK-3475-D46
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
614 enrolled